COPD patients with CAP had lower BMI, more severe obstruction (FEV1%), clinical manifestations (fever, purulent sputum, increased sputum volume) and paraclinical indicators (leukocytosis, decreased eosinophil, increased CRP, changes in arterial blood gas) more severe than exacerbation patients.